{"analyses":[{"ciLowerLimit":"0.02","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.16","groupIds":["OG000","OG001"],"nonInferiorityComment":"To evaluate the noninferiority of MMB over RUX, a conventional 2-sided confidence interval (CI) was calculated for the difference in splenic response rate (SRR) at Week 24: delta = prob(MMB) - 0.6\\*prob(RUX). If the lower bound of the 2-sided 95% CI for delta was greater than 0, MMB was declared noninferior to RUX in SRR at Week 24. The 2-sided 95% CI of delta was calculated based on stratum-adjusted Cochran-Mantel-Haenszel (CMH) proportions. This is the noninferiority proportion difference.","nonInferiorityType":"NON_INFERIORITY","pValue":"0.014","paramType":"Proportion Difference - Stratified CMH","paramValue":"0.09","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"64"}],"title":"Responder"},{"measurements":[{"groupId":"OG000","value":"158"},{"groupId":"OG001","value":"153"}],"title":"Nonresponder"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"215"},{"groupId":"OG001","value":"217"}],"units":"Participants"}],"description":"Splenic response rate at Week 24 is defined as the percentage of participants who achieved a spleen volume reduction of ≥ 35% from baseline at the Week 24 assessment as measured by MRI or CT.","groups":[{"description":"Participants received momelotinib plus placebo to match ruxolitinib.\n\nMomelotinib tablets were administered orally once daily at a starting dose of 200 mg. Additional available strengths included 100 mg and 150 mg.\n\nPlacebo to match ruxolitinib tablets were administered orally twice daily.","id":"OG000","title":"Momelotinib (MMB)"},{"description":"Participants received ruxolitinib plus placebo to match momelotinib.\n\nRuxolitinib tablets were administered orally twice daily. The dose ranged from 5 to 20 mg BID and was dependent on platelet count, creatinine clearance, and transaminase levels.\n\nPlacebo to match momelotinib tablets were administered orally once daily.","id":"OG001","title":"Ruxolitinib (RUX)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Week 24","title":"Splenic Response Rate at Week 24","type":"PRIMARY","unitOfMeasure":"Participants"}